ArticleJAMA network open2024

Premarket Pivotal Trial End Points and Postmarketing Requirements for FDA Breakthrough Therapies.

Maryam Mooghali et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.